admin, Author at Integral Molecular

Published by

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

PHILADELPHIA—Integral Molecular, the leader in antibody discovery against membrane proteins, has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND pilot program. […]

Published by

FDA Announcement: CDER and CBER accept first submission to ISTAND Pilot Program

See statement on FDA website. [9/7/2022] FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted […]

Published by

Genetic Engineering and Integral Molecular Present – Towards IND: Specificity Profiling of Antibody-Based Therapies

Thursday, July 14, 2022 Watch the webinar Rigorous specificity analysis is critical for successful drug development and a safety requirement for monoclonal antibody […]

Published by

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

PHILADELPHIA—Integral Molecular and Optimeos Life Sciences announce a partnership to develop next-generation mRNA and DNA therapeutics that will use antibody-based molecular targeting to direct […]

Published by

Pfaff-Kilgore and colleagues describe a comprehensive mutagenesis and functional study of the E1E2 protein of Hepatitis C virus in Cell Reports

Published in Cell Reports, Pfaff-Kilgore and colleagues describe a comprehensive mutagenesis and functional study (545 individual mutants) of the E1E2 protein of Hepatitis C […]

Published by

Integral Molecular Breaks Ground on New Headquarters, Doubling in Size

PHILADELPHIA—Integral Molecular, the industry leader in membrane protein solutions, announced today that it is starting construction of its new scientific and operational headquarters at […]

Published by

Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics

Basel, Switzerland and Philadelphia, USA, 25 April 2022 – Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and […]

Published by

Integral Molecular Partners with Philadelphia FIGHT Medical Clinic to Support Community Health

Integral Molecular announces a partnership with Philadelphia FIGHT to provide financial and in-kind donations, as well as volunteer efforts to support healthcare access and […]

Published by

RVP Users’ Group: Omicron RVPs and their role in safe neutralization assessment | February 15th, 11am ET

Join this users’ group to learn about our extensive catalog of SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotyped viruses) including Omicron, and how they enable researchers to rapidly test […]

Author: admin

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

FDA Announcement: CDER and CBER accept first submission to ISTAND Pilot Program

Genetic Engineering and Integral Molecular Present – Towards IND: Specificity Profiling of Antibody-Based Therapies

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

Pfaff-Kilgore and colleagues describe a comprehensive mutagenesis and functional study of the E1E2 protein of Hepatitis C virus in Cell Reports

Integral Molecular Breaks Ground on New Headquarters, Doubling in Size

Lonza Early Development Services and Integral Molecular to Offer Complementary Expertise to Enhance Early De-risking of Biotherapeutics

Integral Molecular Partners with Philadelphia FIGHT Medical Clinic to Support Community Health

RVP Users’ Group: Omicron RVPs and their role in safe neutralization assessment | February 15th, 11am ET

Quick Links

Solutions

Contact Us